Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 8/20 | 0.70 |
| ▸ | GABRA5 | P31644 | 8/20 | 0.70 |
| ▸ | GABRA3 | P34903 | 8/20 | 0.70 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.70 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.70 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.70 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.70 |
| ▸ | GABRP | O00591 | 3/20 | 0.70 |
| ▸ | GABRD | O14764 | 3/20 | 0.70 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.70 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.70 |
| ▸ | GABRE | P78334 | 3/20 | 0.70 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.70 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.70 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.70 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3826618 | 0.89 | GABRA1 (0.63) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL13751398 | 0.88 | GABRA1 (0.53) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL16144652 | 0.86 | GABRA1 (0.77) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL3827105 | 0.84 | GABRA1 (0.70) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL3821334 | 0.84 | ALOX12 (0.70) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL16367863 | 0.84 | GABRA1 (0.62) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| SCHEMBL7720989 | 0.83 | GABRA1 (0.77) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Delorazepam SCHEMBL157332 | 0.83 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Delorazepam SCHEMBL29375434 | 0.83 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 | |
| Delorazepam SCHEMBL32681132 | 0.83 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524840-B2 | 7,8-disubstituted pyrazolobenzodiazepines | HOFFMANN-LA ROCHE INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524840-B2 | 7,8-disubstituted pyrazolobenzodiazepines | HOFFMANN-LA ROCHE INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524840-B2 | 7,8-disubstituted pyrazolobenzodiazepines | HOFFMANN-LA ROCHE INC. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-1802625-B1 | DISUBSTITUTED PYRAZOLOBENZODIAZEPINES USEFUL AS INHIBITORS FOR CDK2 AND ANGIOGESIS, AND FOR THE TREATMENT OF BREAST, COLON, LUNG AND PROSTATE CANCER | HOFFMANN LA ROCHE (CH) | 2008-06-18 | — | — | EP | disclosed |
| EP-1802625-B1 | DISUBSTITUTED PYRAZOLOBENZODIAZEPINES USEFUL AS INHIBITORS FOR CDK2 AND ANGIOGESIS, AND FOR THE TREATMENT OF BREAST, COLON, LUNG AND PROSTATE CANCER | HOFFMANN LA ROCHE (CH) | 2008-06-18 | — | — | EP | disclosed |
| EP-1802625-A1 | DISUBSTITUTED PYRAZOLOBENZODIAZEPINES USEFUL AS INHIBITORS FOR CDK2 AND ANGIOGESIS, AND FOR THE TREATMENT OF BREAST, COLON, LUNG AND PROSTATE CANCER | F. Hoffmann-Roche AG (CH) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040036-A1 | DISUBSTITUTED PYRAZOLOBENZODIAZEPINES USEFUL AS INHIBITORS FOR CDK2 AND ANGIOGESIS, AND FOR THE TREATMENT OF BREAST, COLON, LUNG AND PROSTATE CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-20 | — | — | WO | disclosed |
| US-20060079511-A1 | 7,8-Disubstituted pyrazolobenzodiazepines | LIU JIN-JUN | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079511-A1 | 7,8-Disubstituted pyrazolobenzodiazepines | CDK2, CDK1, CDK7 | GABRA1 3202/4885GABRA5 2921/4885GABRA3 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.